Research progress of epigenetic drug decitabine in AML.
10.7534/j.issn.1009-2137.2014.05.054
- Author:
Rui ZHANG
1
;
Hui-Min LI
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China.
2. Department of Hematology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China. E-mail: lihuimin@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Antimetabolites, Antineoplastic;
therapeutic use;
Azacitidine;
analogs & derivatives;
therapeutic use;
Cell Transformation, Neoplastic;
DNA Methylation;
Epigenesis, Genetic;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
genetics
- From:
Journal of Experimental Hematology
2014;22(5):1467-1471
- CountryChina
- Language:Chinese
-
Abstract:
Epigenetics is a gene regulation mechanism that can be reversible and heritable, but do not involve the DNA sequence changes. DNA methylation is one of the most important epigenetic modifications, which is closely correlate with tumorigenesis. Decitabine is a methylation inhibitor, which has different action mechanism and targeting characteristics from the traditional chemotherapy, representing a new therapeutic strategy. This review mainly focuses on the anti-leukemia mechanism of decitabine and its clinical efficacy for AML.
